BeOne Medicines Ltd
06160
Company Profile
Business description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne’s revenue.
Contact
c/o BeOne Medicines I GmbH
Aeschengraben 27
21st Floor
Basel4051
CHET: +41 616851900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
11,000
Stocks News & Analysis
stocks
Outlook for Nvidia and AMD under Trump’s chip plan
In exchange for an export license to China the chip makers will pay the US government 15% of revenue.
stocks
Has the ‘Buffett premium’ gone away for Berkshire?
Shares of Berkshire have plunged more than 12% since May.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.60 | 41.00 | 0.45% |
| CAC 40 | 7,698.52 | 44.48 | -0.57% |
| DAX 40 | 24,081.34 | 81.52 | -0.34% |
| Dow JONES (US) | 43,975.09 | 200.52 | -0.45% |
| FTSE 100 | 9,129.71 | 33.98 | 0.37% |
| HKSE | 24,906.81 | 47.99 | 0.19% |
| NASDAQ | 21,385.40 | 64.62 | -0.30% |
| Nikkei 225 | 41,820.48 | 761.33 | 1.85% |
| NZX 50 Index | 12,911.86 | 67.23 | 0.52% |
| S&P 500 | 6,373.45 | 16.00 | -0.25% |
| S&P/ASX 200 | 8,844.80 | 37.70 | 0.43% |
| SSE Composite Index | 3,647.55 | 12.42 | 0.34% |